# IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

> **NCT05365659** · PHASE1 · RECRUITING · sponsor: **Iksuda Therapeutics Ltd.** · enrollment: 140 (estimated)

## Conditions studied

- B-cell Non-Hodgkin Lymphoma
- Diffuse Large B Cell Lymphoma
- Follicular Lymphoma
- Mantle Cell Lymphoma
- B-cell Lymphoma

## Interventions

- **DRUG:** IKS03

## Key facts

- **NCT ID:** NCT05365659
- **Lead sponsor:** Iksuda Therapeutics Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-05
- **Primary completion:** 2026-09
- **Final completion:** 2028-09
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2025-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05365659

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05365659, "IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05365659. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*